Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prev close 375.59 · gapped above the open, never looked back. High/low 381.04 at 8:00 am ET, 375.59 at 3:45 pm ET.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Substantially all of the Company's Drug Delivery revenue consists of sales of pods to Amgen for use in the Neulasta ® Onpro ® kit, a delivery system for Amgen's Neulasta to help reduce the risk of infection after intense chemotherapy.”
FILING10-K0001145197-25-000007cik 0001145197disclosed by PODD
“Concurrent with the entry into the Amgen Agreement, Amgen purchased 1,156,069 shares of our common stock for $20.0 million.”
FILING10-K0001193125-26-107146cik 0001501989disclosed by CTMX
“14 Amgen 1 1 163,169 6,833 0.8% 3.8”
FILING10-K0000025232-25-000012cik 0000025232disclosed by CUZ
“On May 8, 2023, the Company entered into a Collaboration Agreement with Amgen Inc. (the Amgen Agreement) to identify antigens recognized by T cells in patients with Crohn's disease in accordance with a research plan.”
FILING10-K0001193125-26-089884cik 0001783328disclosed by TCRX
“The Amgen Collaboration Agreement automatically terminated upon its third anniversary in September 2024 and a final payment was made to Amgen in May 2025.”
FILING10-K0001193125-26-130388cik 0001885522disclosed by NMRA
“At the initiation of the collaboration, we had the option to select from programs specified in the Amgen Agreement, an existing preclinical stage TCE product from the Amgen preclinical pipeline.”
FILING10-K0001193125-26-107146cik 0001501989disclosed by CTMX
“For example, in 2019, we entered into a strategic collaboration with Amgen with respect to its commercial-stage oncology products XGEVA ® , BLINCYTO ® and KYPROLIS ® and a portfolio of clinical- and late-preclinical-stage oncology pipeline products.”
FILING10-K0001628280-26-011946cik 0001651308disclosed by ONC
“In connection with the Settlement Agreement, we entered into a License and Covenant Agreement with Amgen in which we agreed to pay Amgen low single-digit royalty payments on net sales of our products that, but for the license, could be found to infringe a valid Amgen patent on a country-by-country and product-by-product basis.”
FILING10-K0001628280-26-045886cik 0001737953disclosed by REPL
“In February 2017, we entered into the RP OM RPA pursuant to which we sold a portion of our right to receive royalties from Amgen on future net sales of omecamtiv mecarbil to RPFT for a one-time payment of $90 million, which is non-refundable even if omecamtiv mecarbil is never commercialized.”
FILING10-K0001193125-26-076495cik 0001061983disclosed by CYTK
“On September 28, 2016, Amgen and the Company entered into two collaboration and license agreements and a common stock purchase agreement.”
FILING10-K0000879407-25-000029cik 0000879407disclosed by ARWR
“Our royalty portfolio includes products marketed by leading biopharmaceutical companies such as Amgen, Merck, Jazz, Recordati, and Sanofi.”
FILING10-K0000886163-26-000006cik 0000886163disclosed by LGND
“We have active customer engagements primarily focused across pharmaceuticals, materials science, financial services, government and industrial markets, including with market leaders, such as JPMorgan Chase in financial services, Amgen in pharmaceuticals, Mitsui & Co. in cybersecurity and Honeywell in chemistry, each of whom serves as both a customer and an innovation partner”
FILINGS-1/A0001628280-26-039286cik 0002110105disclosed by QNT
“In addition, the Generate Platform’s modular capabilities underpin the confidential programs being developed in collaboration with Amgen Inc. ("Amgen") and Novartis Pharma AG ("Novartis").”
FILINGS-1/A0001193125-26-062362cik 0002100782disclosed by GENB
Watchlist prices, news filtered to it, and its next report on your desk.
Amgen Inc
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
Amgen Inc has 9 disclosed suppliers and 4 disclosed customers. Each one is named in an SEC filing, either Amgen Inc’s own annual report or the counterparty’s, and carries the sentence that discloses it.
AMGN (Amgen Inc) has 9 disclosed suppliers and 4 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: NMRA −16.93%, in healthcare.